- STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain diseaseOak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman syndrome medicine.STAT · 7h ago↗ source
- [Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services<p>This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.</p>BioPharma Dive · 7h ago↗ source
- [Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus<p>This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.</p>